Mesoblast has crossed the FDA-commercialization threshold with a 93% gross-margin cell therapy, but the next valuation step-change hinges on a binary Phase 3 back-pain readout and scalable CMC execution.
Overview
Mesoblast Limited is transitioning from a clinical-stage biotechnology company into a commercial-stage regenerative medicine enterprise built around off-the-shelf (allogeneic) cellular therapies derived from mesenchymal lineage cells. Its defining milestone is late 2024 FDA approval of Ryoncil® (remestemcel‑L), the first and only MSC therapy approved in the U.S., supporting a rapid commercial ramp after a March 2025 launch. Revenue is now generated through U.S. product sales and ex‑U.S. licensing/royalties, with H1 FY2026 revenue of ~$51.3M including ~$49M from Ryoncil®, and an exceptional ~93% gross margin that highlights scalability of industrial allogeneic manufacturing. The pipeline expands the same platform into much larger markets—adult SR-aGvHD, chronic low back pain, and inflammatory heart failure—collectively cited as >$20B TAM. The investment profile is increasingly “commercial plus catalysts”: strong early uptake and high-margin economics support the base business, while the next major re-rating depends on pivotal CLBP execution and further regulatory expansions, funded in part by a $125M non-dilutive shareholder credit facility.